It was great speaking live with Joel Brierre at the Psychedelic Therapeutics & Drug Development Conference in New Orleans a few weeks ago. We discussed how Five Discovery is developing non-hallucinogenic analogs of 5-MeO-DMT, and why these compounds could open new therapeutic avenues for neurodegenerative disease and brain injury. Watch the replay to learn more about the strategy behind these next-generation neuroplastogens. Interview conducted as part of Cascades Analytics’ live coverage of PTDDC, in partnership with Arrowhead SciTech Conferences & Events.